Go to interview with John Mackey, MD
Interview with a Woman with Breast Cancer
Go to interview with Maureen Major, RN, MS
Go to interview with with Clifford Hudis, MD
 
 
To listen to individual tracks now, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
     
John Mackey, MD
Medical Oncologist,
Cross Cancer Institute Associate
Professor of Oncology
University of Alberta Chair, Northern Alberta Breast Cancer Program
Director, Cancer International Research Group
Edmonton, Canada
  
  Click here to download the entire interview  
     
Track 1 Introduction by Neil Love, MD
Track 2 Overview of aromatase inhibitors
Track 3 Mechanism of action of aromatase inhibitors
Track 4 Efficacy of aromatase inhibitors versus tamoxifen
Track 5 Survival benefit of aromatase inhibitors versus tamoxifen
Track 6 Endometrial changes associated with tamoxifen
Track 7 Impact of aromatase inhibitors on bone density
Track 8 Vasomotor symptoms and vascular toxicities associated with tamoxifen
Track 9 Arthralgias associated with aromatase inhibitors
Track 10 Clinical trials of aromatase inhibitors in the adjuvant setting
Track 11 Clinical implications of the adjuvant aromatase inhibitor trials
Track 12 Aromatase inhibitors combined with LHRH agonists in premenopausal patients
Track 13 Oncotype DX™: Predictive assay for the use of adjuvant chemotherapy
Track 14 Use of the Oncotype DX assay in clinical practice
Track 15 Clinical trials of trastuzumab for HER2-positive breast cancer
Track 16 BCIRG 006: Adjuvant trial of docetaxel/carboplatin/trastuzumab
Track 17 Predictive assay for the use of anthracycline-based chemotherapy
Track 18 Delayed treatment of patients with HER2-positive breast cancer who did not receive
adjuvant trastuzumab
Track 19 Combining trastuzumab with dose-dense chemotherapy
Track 20 Adjuvant trastuzumab in patients with node-negative breast cancer
Track 21 Single-agent trastuzumab as adjuvant therapy in elderly patients
     
  Interview with a Woman with Breast Cancer
  
  Click here to download the entire interview  
     
Track 1 Introduction by Neil Love, MD
Track 2 Patient interview: A 45-year-old woman with HER2-positive, node-positive breast cancer on an adjuvant trastuzumab clinical trial
Track 3 Dealing with a diagnosis of breast cancer
Track 4 Enrolling in a clinical trial
Track 5 Early closure of the adjuvant trastuzumab trial
     
Maureen Major, RN, MS
 Clinical Nurse Specialist
Evelyn H Lauder Breast Center Memorial
Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
     
Track 1 Introduction by Neil Love, MD
Track 2 Case discussion: 67-year-old patient with hormone receptor-positive, HER2-negative, node-negative breast cancer
Track 3 Chemotherapy decisions for patients with comorbidities
Track 4 Integrating the Oncotype DX assay into clinical practice
Track 5 Managing side effects of chemotherapy
Track 6 Adjuvant endocrine therapy for postmenopausal patients
Track 7 Nursing management of arthralgias secondary to aromatase inhibitors
Track 8 Women’s Intervention Nutrition Study: Dietary fat reduction in postmenopausal women with primary breast cancer
Track 9 Counseling patients about aromatase inhibitors
Track 10 Using the Oncotype DX score when deciding on adjuvant chemotherapy
Track 11 Counseling patients on diet and exercise during treatment for breast cancer
     
Clifford Hudis, MD
Chief, Breast Cancer Medicine Service
Solid Tumor Division Memorial
Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download the entire interview  
     
Track 1 Introduction by Neil Love, MD
Track 2 Clinical indications for the Oncotype DX assay
Track 3 Impact of the Oncotype DX assay on relative risk and cost
Track 4 Mechanism of action of bevacizumab
Track 5 Clinical trials of bevacizumab in breast cancer
Track 6 Side effects of bevacizumab
Track 7 Chemotherapy with bevacizumab in metastatic disease
Track 8 Single-agent bevacizumab in metastatic disease
Track 9 Potential benefit of bevacizumab combined with chemotherapy
Track 10 Clinical management of triple-negative breast cancer
Track 11 Novel schedule of capecitabine therapy
Track 12 Combined bevacizumab and capecitabine in metastatic breast cancer
Track 13 Bevacizumab in the adjuvant setting
Track 14 Duration of bevacizumab therapy
Track 15 Bevacizumab: Therapy targeting VEGF receptors on tumor cells
Track 16 Mechanism of action of fulvestrant
Track 17 Selecting hormonal therapy for metastatic disease
Track 18 Patient preferences for oral therapy versus intramuscular injection
Track 19 Dosing and novel combinations with fulvestrant
Track 20 Delayed fulvestrant in the adjuvant setting
Track 21 Risk of recurrence in ER-positive and ER-negative disease